Vitamin A Compound Or Derivative Patents (Class 514/725)
-
Patent number: 6379683Abstract: The present invention relates to nanocapsules consisting of a lipid core forming or containing a lipophilic active principle, and of a water-insoluble continuous envelope comprising at least one dendritic polymer of polyester type containing optionally modified terminal hydroxyl functions, and to cosmetic and/or dermatological compositions containing the said nanocapsules based on dendritic polymers.Type: GrantFiled: February 22, 2000Date of Patent: April 30, 2002Assignee: L'OrealInventors: Jean-Thierry Simonnet, Pascal Richart
-
Publication number: 20020048580Abstract: The invention relates to a method of treating lung branching malformation in a subject by administering to the subject a pharmaceutically effective amount of a retinoic acid receptor (RAR) retinoid. The invention also relates to a method of increasing alveoli in a subject by administering a pharmaceutically effective amount of a retinoic acid receptor (RAR) antagonist. The invention further relates to a method of inducing primary lung bud formation in a subject by administering a pharmaceutically effective amount of a retinoic acid receptor agonist. The invention also relates to a method of identifying an agent capable of inducing primary lung bud formation, the method comprising: (a) administering an agent to an embryo; and (b) determining primary lung bud formation of said embryo.Type: ApplicationFiled: June 7, 2001Publication date: April 25, 2002Applicant: Institut National De La Sante Et De La Recherche MedicaleInventors: Richard Mollard, Pierre Chambon, Manuel Mark
-
Patent number: 6372753Abstract: Proliferation of retinal pigment epithelium following surgery or trauma or resulting in ocular diseases associated with choroidal neovascularization, such as age related macular degeneration and histoplasmosis syndrome, is prevented by contacting retinal pigment epithelium cells with a therapeutic amount of a retinoic acid receptor (RAR agonist, preferably one with specific activity for retinoic acid receptors. Preferably the RAR agonist is also a potent antagonist of AP1-dependent gene expression. Alternatively, the proliferation of retinal pigment epithelium is ameliorated with a therapeutic amount of an AP-1 antagonist, alone or in combination with an RAR agonist. The drug can be administered by bolus injection into the vitreous cavity using a dosage from about 50 to 150 &mgr;g. Or by slow release from liposomes or an oil tamponade injected into the vitreous cavity. Formulations for preventing proliferation of retinal pigment epithelium are also provided.Type: GrantFiled: March 27, 2000Date of Patent: April 16, 2002Assignees: Allergan, The Johns Hopkins University School of MedicineInventors: Peter A. Campochiaro, Larry A. Wheeler, Roshantha A. Chandraratna, Sunil Nagpal, Eugene De Juan, Jr.
-
Publication number: 20020041890Abstract: Cosmetic skin care methods and compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof. The inventive compositions provide control of sebum secretion from sebocytes, improved oil control and improved skin feel, prevent shine and stickiness, while also providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin color, treatment of photoaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin.Type: ApplicationFiled: June 1, 2001Publication date: April 11, 2002Applicant: Unilever Home & Personal Care USA, Division of Conopco, Inc.Inventors: Bijan Steven Harichian, Laurence Boen, John Steven Bajor
-
Patent number: 6365623Abstract: Active acne and acneiform scars are treated by topical application of a composition containing lipoic acid and/or a lipoic acid derivative such as dihydrolipoic acid, a lipoic or dihydrolipoic acid ester, a lipoic or dihydrolipoic acid amide, a lipoic or dihydrolipoic acid salt, and mixtures of any of these to reduce erythema, pore size, and scarring. Topical application of lipoic acid and/or a lipoic acid derivatives are advantageously used with at least one adjunct ingredient such as a retinoid, an antibiotic, or benzoyl peroxide conventionally used for acne, alone or in combination with dimethylaminoalcohol, an &agr;-hydroxy acid such as glycolic acid, a tyrosine, tocotrienol, and/or a fatty acid ester of ascorbic acid. One preferred embodiment contains a combination of lipoic acid, an &agr;-hydroxy acid, and dimethylaminoalcohol.Type: GrantFiled: December 30, 1999Date of Patent: April 2, 2002Inventor: Nicholas V. Perricone
-
Patent number: 6365630Abstract: Compositions and methods are provided for ameliorating various effects of UVA and UVB radiation from the sun. The compositions including an ingredient that prevents photoaging from MED and subMED radiation, such as a retinoid, certain other compounds (such as N-acetylcysteine, 2-furildioxime, and vitamin C) and optionally other MMP inhibitors such as tetracyclines and/or compounds that inhibit the P-450-mediated metabolism of retinoids such as ketoconazole and other azole compounds. In the method, the composition is applied prior to exposure to the sun; depending upon the ingredients used in the composition, application should be from 7 to 48 hours prior to exposure. Compounds that prevent erythema (skin reddening, sunburn) do not necessarily protect against UV-mediated elevation of MMP levels and activity, and similarly compounds that prevent UV-mediated elevation of MMP levels and activity are not necessarily effective against UV-induced erythema.Type: GrantFiled: July 13, 2000Date of Patent: April 2, 2002Assignee: Regents of the University of MichiganInventors: Gary J. Fisher, John J. Voorhees, Sewon Kang
-
Publication number: 20020037855Abstract: The invention relates to a stabilized medicament with an amount of active ingredients containing cysteine groups and NSAID compounds, wherein a stabilization of the combination, especially the active ingredients containing the cysteine group, can be conducted with a mixture of at least three anti-oxidative components. The therapeutic and prophylactic use of this medicament stabilized in this manner lies in the field of the prevention and therapy of inflammatory diseases among the fields of medical indications.Type: ApplicationFiled: March 22, 2001Publication date: March 28, 2002Inventor: Fritz Stanislaus
-
Publication number: 20020028849Abstract: Disclosed is the use of retinoids such as retinol, all trans retinoic acid, and 9-cis retinoic acid to enhance the success of assisted-reproduction. Administration of retinol to superovulated animals dramatically improved embryo viability and development as well as the pregnancy rates of animals implanted with embryos derived from such animals. Culturing presumptive embryos in vitro in the presence of retinol enhanced development of embryos from the presumptive zygotes compared to presumptive embryos not treated with retinol.Type: ApplicationFiled: April 17, 2001Publication date: March 7, 2002Inventors: James D. Godkin, Dawn M. Eberhardt
-
Patent number: 6353029Abstract: A long-term storage stable tretinoin and 4-hydroxyanisole composition contains low molecular weight polyethylene glycol, antioxidant, a chelating agent, lower alkanol and water. The chelating agent provides at least two of the functions of oxygen scavaging, free radical chain terminating and reducing. The composition has a pH of 2.5 to 5 and a water content of at least 12%.Type: GrantFiled: August 24, 2000Date of Patent: March 5, 2002Assignee: Bristol-Myers Squibb CompanyInventor: Prakash V. Parab
-
Patent number: 6350785Abstract: The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.Type: GrantFiled: January 19, 2001Date of Patent: February 26, 2002Assignee: Maxim Pharmaceuticals, Inc.Inventor: Kurt R. Gehlsen
-
Publication number: 20020018792Abstract: Anti-sebum skin care methods and compositions containing TCC. The compositions are non-greasy and aesthetically pleasing, and provide control of sebum secretion from sebocytes, improved oil control and improved skin feel, and prevent shine and stickiness.Type: ApplicationFiled: June 1, 2001Publication date: February 14, 2002Applicant: Unilever Home & Personal Care USA, Division of Conopco, Inc.Inventors: Bijan Steven Harichian, John Steven Bajor, Kathy Anne Lanza, Surajit Mukherjee
-
Patent number: 6344206Abstract: A composition comprising the combination of at least one retinoid selected from the group consisting of vitamin A (retinol) and the bioconvertible precursors of vitamin A and at least one polyamine polymer.Type: GrantFiled: August 31, 2000Date of Patent: February 5, 2002Assignee: L'OrealInventors: Quang Lan Nguyen, Boudiaf Boussouira, Stephanie Prince, Paolo Giacomoni
-
Publication number: 20020012641Abstract: Photoaging of human skin, such as evidenced by the increased presence of matrix metalloproteinases after exposure to UV radiation, is prevented by pretreating the skin with an inhibitor of epidermal growth factor receptor (EGF-R) prior to exposure. Such inhibitor are preferably natural, an example of which is genistein. Compositions used for such purposes preferably include an EGF-R as well as another MMP inhibitor, such as a retinoid.Type: ApplicationFiled: June 26, 2001Publication date: January 31, 2002Inventors: John J. Voorhees, Gary J. Fisher
-
Publication number: 20020006418Abstract: This invention relates to compositions and methods for enhancing the penetration of topical skin agents into the skin wherein said compositions contain at least one active ingredient, a skin conditioner and a polymeric emulsifier.Type: ApplicationFiled: July 27, 1999Publication date: January 17, 2002Inventors: JOHN KUNG, JUE-CHEN LIU, SUSAN NIEMIEC
-
Patent number: 6339107Abstract: The current invention is directed to methods of treating or preventing emphysema, pharmaceutical compositions suitable for the treatment or prevention of emphysema and methods for delivering formulations into the lung of a mammal suffering from emphysema. More generally, the invention encompasses the use of 13-cis-retinoic acid to treat or prevent certain chronic obstructive airway disorders, particularly chronic obstructive pulmonary disease including chronic bronchitis, emphysema and asthma in mammals, especially humans that smoke or smoked cigarettes. In another aspect, the present invention encompasses the use of pharmaceutical compositions of 13-cis-retinoic acid to treat emphysema. Moreover, the current invention encompasses the use of electrohydrodynamic aerosol devices, aerosol devices and nebulizers to deliver formulations of 13-cis-retinoic acid into the lung of a mammal suffering from emphysema. The invention also encompasses the systemic use as well as the local use of 13-cis-retinoic acid.Type: GrantFiled: August 2, 2000Date of Patent: January 15, 2002Assignee: Syntex (U.S.A.) LLCInventor: Paula N Belloni
-
Patent number: 6334999Abstract: To optimize the delivery of all-trans retinoic acid to lung tissue, the potential of vehiculating this drug in liposomes and delivering it via aerosol was determined. Liposomes provide a means to prevent local irritation of lung tissue, reduce pulmonary toxicity, prolong therapeutic levels, and generate high drug concentrations at the tumor sites. Therefore, the delivery of ATRA to the lung tissue in mice was accomplished by nebulization of L-ATRA. The liposomes in the aerosol were uniform, stable, and retained the drug well. The drug was effectively delivered at high concentrations to the lungs of mice and was retained at least up to 96 h after a single exposure to L-ATRA aerosols. The aerosol-delivered ATRA was biologically active as demonstrated by its ability to induce the expression of tissue-type transglutaminase. Aerosol delivery of L-ATRA offers an effective way to deliver high levels of ATRA to the lung without apparent pulmonary toxic effects.Type: GrantFiled: August 27, 1999Date of Patent: January 1, 2002Assignee: Research Development FoundationInventors: Brian E. Gilbert, Ranjani Parthasarathy, Kapil Mehta
-
Publication number: 20010056071Abstract: The use of resveratrol (3,4′,5-trihydroxy-trans-stilbene) and derivatives thereof, for the preparation of medicaments for the treatment of exfoliative eczema, acne and psoriasis, topical pharmaceutical formulations containing resveratrol or derivatives thereof in combination with other active principles. Treatment consists in topical administrations of resveratrol at concentrations of 0.01 to 20%, in the form of lotions, creams or ointments, optionally in combination with other active principles such as melatonin, vitamins D, E and A and derivatives thereof, hormones, vegetable and/or animal extracts. Contrary to current therapies, the use of resveratrol has neither systemic nor topical effects during and after therapy.Type: ApplicationFiled: March 22, 2001Publication date: December 27, 2001Inventors: Maria Teresa Pelliccia, Attilio Giannella, Jenny Giannella
-
Publication number: 20010051602Abstract: Disclosed herein is a method for reducing neurodegenerative disease in patients by administration of a therapeutically-effective amount of a compound which can increase ApoE levels.Type: ApplicationFiled: June 22, 2001Publication date: December 13, 2001Inventor: Judes Poirier
-
Patent number: 6329414Abstract: Nutriceutical compositions useful as a dietary supplement which have antioxidant/free radical scavengers and also having a cytoprotective effect are disclosed. The compositions contain a cytoprotective and antioxidant/free radical scavenging amount of at least one of D-histidine, L-histidine, a racemic mixture thereof, a non-racemic mixture thereof, and nutriceutically acceptable salts thereof in combination with phytonutrients having antioxidant properties such as canthanaxin, vitamin A and limonene. The compositions can be prepared in capsule form, tablets, sustained release tablets, suspensions and oral rehydration solutions.Type: GrantFiled: September 10, 1999Date of Patent: December 11, 2001Assignee: Cytos Pharmaceuticals LLCInventors: Peter G. Thomas, A. Michael Wade
-
Patent number: 6329432Abstract: Meso-zeaxanthin compositions for pharmaceutical use and use of meso-zeaxanthin to increase the deposition of macular pigment in the human eye, and for the therapeutic treatment or prophylaxis of diseases and disorders of the macula, in particular age-related macular degeneration (AMD).Type: GrantFiled: March 2, 2001Date of Patent: December 11, 2001Assignee: The Howard FoundationInventors: Alan Norman Howard, John T. Landrum, Richard A. Bone
-
Patent number: 6328995Abstract: Stable dry powders which are insoluble in hot water and which contain one or more lipid-soluble vitamins an/or one or more carotenoids are formed in an aqueous dispersion containing 2 to 50% by weight of at least one protein, 1 to 30% by weight of at least one sugar, 0.2 to 20% by weight of K2HPO4, Na2HPO4 or mixtures thereof, 0.1 to 20% by weight of at least one lipoid-soluble vitamin and/or at least one carotenoid and 5 to 95% of water. This dispersion is converted into dry powder which is heated in the range of 55° C. to 1800° C.Type: GrantFiled: September 24, 1999Date of Patent: December 11, 2001Assignee: BASF AktiengesellschaftInventors: Wolfgang Bewert, Roland Betz, Peter Schmitt, David Kenneth Bower, Frederick Kenneth Chaundy
-
Patent number: 6326034Abstract: An antioxidant composition is isolated and purified from natural sources including yeast (S. carlsbergenesis, S. cerevisiae, or commercial yeast extract), and saltbush (Atriplex halimus), or synthesized chemically, by processes that improve the potency of the product. Compositions containing natural and synthetic compounds, with or without chromium, possessing antioxidant activity are formulated for use in animals and humans. Methods for use of the natural and synthetic antioxidants, alone or in combination with other antioxidant agents, for regulating oxidative conditions are presented.Type: GrantFiled: December 22, 1999Date of Patent: December 4, 2001Assignee: Natural Compounds LTDInventors: Nitsa Mirsky, Alona Schachter, Sherbel Sussan
-
Patent number: 6326355Abstract: The present invention relates to methods and nutritional compositions for the prevention and treatment of cachexia and anorexia. The methods of the invention comprise administering a composition comprising effective amounts of &ohgr;-3 fatty acids such as alpha-linolenic acid, stearidonic acid, eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid or mixtures thereof, of branched-chain amino acids valine, leucine, isoleucine or mixtures thereof; with or without reduced levels of tryptophan and 5-hydroxytryptophan; and of antioxidant system selected from the group comprising beta-carotene, vitamin C, vitamin E, selenium, or mixtures thereof.Type: GrantFiled: January 7, 2000Date of Patent: December 4, 2001Assignee: Abbott LaboratoriesInventors: Bonnie Chandler Abbruzzese, Mark Anthony McCamish, Frederick Oliver Cope, Stephen Joseph Demichele
-
Patent number: 6322821Abstract: A composition for preventing and treating milk fever in freshening cows, and a method of administering the composition. The basic composition is a mixture of water, calcium chloride, propylene glycol, B vitamins and minerals. The calcium content is lower than conventional calcium treatments used for this purpose. The propylene glycol gives the cow an energy boost and sweetens the taste so the cow does not object to it as it does to conventional gels and liquids. The B vitamins stimulate the cow's appetite. The minerals replace minerals lost in the milk and also help the cow absorb calcium. The composition of the present invention is in a liquid form and is preferably administered using a 200-300 cc drench gun. The end of the dispensing tube of the drench gun is placed between the teeth and cheek of the cow near the receptors that stimulate the esophageal groove reflex.Type: GrantFiled: September 27, 1999Date of Patent: November 27, 2001Inventor: Jack W. Register
-
Patent number: 6319957Abstract: Compositions based on glyco-alcohol, hydro-alcohol or glyco-hydro-alcohol solutions of a glycol or glyceric ester of retinoic acid, preferably in association with the ethyl ester of retinoic acid and with hydroquinone, have been found to be particularly effective, as such or in cream form, in eliminating unsightly skin disorders such as acne, wrinkles, scars, stretch marks, dark spots, etc., and in treating mycotic skin diseases and psoriasis.Type: GrantFiled: December 24, 1997Date of Patent: November 20, 2001Inventor: Khodor Ammar
-
Publication number: 20010041695Abstract: Applicants have discovered that L-carnitine increases the intestinal (lymphatic) absorption of fat soluble vitamins, such as vitamins A, D, and E, in post-menopausal women. As a result, L-carnitine enhances the antioxidant defense mechanism and lowers the risk of certain degenerative diseases, such as coronary heart disease, age-related macular degeneration, osteoporosis, cancer, and Alzheimer's, in post-menopausal women. The present invention provides a method for increasing the intestinal absorption, cellular concentration, biliary secretion, hepatic storage, and/or liver concentration of a fat soluble vitamin in a post-menopausal woman. The method comprises orally administering to a post-menopausal woman in need thereof, a fat soluble vitamin and a fat soluble vitamin absorption increasing effective amount of L-carnitine. The invention also provides a method for increasing the intestinal absorption of a fat soluble vitamin in an animal.Type: ApplicationFiled: March 1, 2001Publication date: November 15, 2001Inventors: Sung I. Koo, Kathy Lynn Gross, Kevin Owen
-
Patent number: 6316404Abstract: This invention relates to methods and compositions for the treatment of non-insulin-dependent diabetes mellitus using an RXR agonist alone or in combination with a PPAR&ggr; agonist such as a thiazolidinedione compound.Type: GrantFiled: December 22, 2000Date of Patent: November 13, 2001Assignee: Ligand Pharmaceuticals IncorporatedInventors: Richard A. Heyman, Rosemary Cesario, Ranjan Mukherjee
-
Patent number: 6313168Abstract: The present invention relates to methods for treating cartilage and bone pathologies, including bone growth related diseases such as osteoarthritis, comprising administering therapeutically effective amounts of retinoid receptor antagonists.Type: GrantFiled: December 15, 1999Date of Patent: November 6, 2001Assignee: Allergan Sales, Inc.Inventors: Maurizio Pacifici, Roshantha A. Chandraratna
-
Patent number: 6309677Abstract: A composition is provided that includes carotenoid extracts derived from a plurality of natural sources. Carotenoids are extracted from natural sources such as palm fruit, algae and marigold flowers and combined in a single product. The product may include carriers such as yellow bees wax, soybean oil and lecithin and may be in a form suitable for oral ingestion.Type: GrantFiled: March 24, 1998Date of Patent: October 30, 2001Assignee: Amway CorporationInventors: David Gorenbein, Idrees A. Siddiqui, Ernie R. Ceja, Christine M. Horvath
-
Patent number: 6310090Abstract: A process for feeding a companion animal such as a dog a diet containing an effective amount of a combination of antioxidants to enhance immune response and improve the overall health of the animal is provided. Preferably, the diet includes from about 175 to about 400 IU of vitamin E per kilogram of diet, from about 1 to about 50 mg/day of lutein, and from about 1 to about 50 mg/day of &bgr;-carotene.Type: GrantFiled: May 26, 2000Date of Patent: October 30, 2001Assignee: The Iams CompanyInventor: Michael G. Hayek
-
Patent number: 6306426Abstract: An implant device is provided which incorporates a retinoid for improving the biocompatibility of the device in tissue. The device may be bioerodible for the purpose of systemically or locally releasing a therapeutic agent in tissue or it may be a permanent implant which includes a surface treated with a retinoid for increasing the biocompatibility thereof.Type: GrantFiled: June 5, 2000Date of Patent: October 23, 2001Assignee: Allergan Sales, Inc.Inventors: Orest Olejnik, Patrick M. Hughes, John S. Kent
-
Patent number: 6306430Abstract: A process is provided for reducing adiposity in an animal such as a companion animal by feeding the animal an effective amount of Vitamin A for a time sufficient to reduce adiposity in the animal. Preferably, the such effective amount comprises from about 50,000 IU to about 1,000,000 IU of Vitamin A per kilogram of diet. Such an effective amount provides sufficient Vitamin A to decrease accumulation of body fat, increase UCP1 levels, and decrease serum leptin levels in the animal.Type: GrantFiled: April 9, 1999Date of Patent: October 23, 2001Assignee: The Iams CompanyInventors: Gregory D. Sunvold, Michael G. Hayek
-
Publication number: 20010031744Abstract: This invention relates to nutrient and therapeutic compositions for treatment and prevention of symptoms and disease conditions associated with microangiopathy and macroangiopathy and to methods using the compositions. In particular, the invention relates to compositions useful in the treatment of diabetic retinopathy and nephropathy, to compositions useful in the treatment of other retinal disorders including macular degeneration and cataracts, to compositions useful in wound healing, to compositions useful for treatment and prevention of neuropathy, to compositions useful for treatment and prevention of cardiovascular disease and to compositions useful for the treatment and prevention of dental and periodontal disorders.Type: ApplicationFiled: April 5, 2001Publication date: October 18, 2001Inventor: John V. Kosbab
-
Patent number: 6303112Abstract: A wound healant composition comprising a therapeutically effective amount of activated growth factors and ascorbic acid and/or at least one retinoid and/or at least one antibiotic, that facilitates the growth of new tissue.Type: GrantFiled: November 23, 1999Date of Patent: October 16, 2001Inventor: Charles E. Worden
-
Patent number: 6300369Abstract: The subject of the present invention is a hydroxy-kojic acid skin peel.Type: GrantFiled: February 22, 1999Date of Patent: October 9, 2001Inventor: Margaret Ancira
-
Patent number: 6300377Abstract: The present invention relates to a composition in liquid dosage form of coenzyme Q or ubiquinone which can be formulated into cosmetic, dietary supplement or pharmaceutical dosage form for administration to patients. The dosage form comprises an effective amount of coenzyme Q or ubiquinone ranging from about 0.05% to about 15%, more preferably about 1% to about 10.0% by weight of the composition in combination with a polysorbate surfactant such as a Tween™, surfactant, a vegetable oil or triglyceride, in further combination with a glyceryl ester in amounts effective to produce a liquid dosage form. Optional additives include a phospholipid such as hydroxylated lecithin, among others such as tocopherols or tocopherol esters effective to solubilize the ubiquinone in combination as well as other bioactive agents. Compositions according to the present invention avoid the inclusion of a polyhydric alcohol solvent in solubilizing amounts.Type: GrantFiled: February 22, 2001Date of Patent: October 9, 2001Inventor: Raj K. Chopra
-
Publication number: 20010027216Abstract: The present invention provides a method for preventing the adverse effects which may be associated with the administration of at least one hormone to a subject without detectable cancer comprising administering to such subject at least one carotenoid. The invention further provides a method for preventing a variety of adverse effects associated with the administration of hormones, including, for example, an increased risk for developing cancer. The invention further provides a method for preventing adverse effects without inhibiting the beneficial activity of the hormone. The invention further provides a method for preventing the adverse effects associated with administration of estrogen and/or progestin in hormone replacement therapy without inhibiting the beneficial activity of such hormone. The invention further provides a method for preventing the adverse effects associated with the administration of phytoestrogens.Type: ApplicationFiled: March 5, 2001Publication date: October 4, 2001Inventors: Joseph Levy, Yoav Sharoni
-
Publication number: 20010022978Abstract: The invention relates to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist in a cosmetic, pharmaceutical or dermatological composition for treating sensitive skins. It relates especially to the use of a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist for preventing and/or combating skin irritations and/or sores and/or erythema and/or dysaesthesic sensations and/or sensations of inflammation and/or pruritus and/or prickling and/or tingling and/or discomfort and/or tightness of the skin and/or mucosae. It also relates to a composition containing a histamine antagonist, an interleukin-1 antagonist and/or a TNF-alpha antagonist which limits or eliminates the irritant side-effects of certain products, and in particular of certain cosmetic, dermatological or pharmaceutical active agents.Type: ApplicationFiled: April 25, 2001Publication date: September 20, 2001Inventors: Olivier De Lacharriere, Lionel Breton, Catherine Cohen
-
Publication number: 20010023256Abstract: The present invention relates to a method for preventing and/or reducing cellular and tissue damage caused by reactive oxygen metabolites (ROMs) released by phagocytic or endothelial cells in response to various disease states or pathologies. The methods of the present invention are useful in preventing and treating a variety of disease states or pathological situations in which ROMs are produced and released. The methods of the present invention contemplate reducing ROM-mediated damage by reducing the production and release of ROMs.Type: ApplicationFiled: April 12, 2001Publication date: September 20, 2001Inventors: Kristoffer Hellstrand, Svante Hermodsson, Kurt R. Gehlsen
-
Patent number: 6291519Abstract: A method for preventing damage to mammalian eye tissues by UV-irradiation and ozone by applying to the eye a pharmaceutically effective amount of vitamin A and vitamin E.Type: GrantFiled: October 8, 1999Date of Patent: September 18, 2001Assignee: Novartis AGInventor: György Lajos Kis
-
Patent number: 6291533Abstract: Dietary supplement compositions designed to be responsive to specific blood types, and thus most beneficial for people with specific antigenic blood types.Type: GrantFiled: December 22, 1999Date of Patent: September 18, 2001Assignee: Vitamerica, Inc.Inventor: Albert M. Fleischner
-
Patent number: 6284802Abstract: The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a composition comprising: a) a safe and effective amount of farnesol; and b) a dermatologically-acceptable carrier for the farnesol. In additional embodiments, the above composition is suitable for thickening skin and preventing and/or retarding atrophy of mammalian skin, preventing and/or retarding the appearance of spider vessels and/or red blotchiness on mammalian skin, preventing and/or retarding the appearance of dark circles under the eye of a mammal, preventing and/or retarding sallowness of mammalian skin, preventing and/or retarding sagging of mammalian skin, softening and/or smoothing lips, hair and nails of a mammal, and preventing and/or relieving itch of mammalian skin.Type: GrantFiled: April 4, 2000Date of Patent: September 4, 2001Assignee: The Procter & Gamble CompanyInventors: Donald Lynn Bissett, Elizabeth Ann Jewell-Motz
-
Publication number: 20010016206Abstract: A capsule system for oral delivery of an active agent having low aqueous solubility generally includes, in combination with the active agent, a vehicle for preventing initial active agent dissolution within the gastrointestinal tract and an emulsifier for promoting self-emulsification of the active agent and vehicle in the gastrointestinal tract. A capsule shell is provided for encapsulating the active agent, vehicle and emulsifier with the shell being formulated to open upon ingestion into the gastrointestinal tract and release the active agent and vehicle.Type: ApplicationFiled: January 12, 2001Publication date: August 23, 2001Inventors: Bruce A. Firestone, Thao T. Tran
-
Patent number: 6277890Abstract: This invention relates to the use of retinoic acid, its esters and analogues thereof for enhancing alveolar function or development. The method comprises administration of a composition containing an alveoli formation-inducing effective amount of a retinoic acid, its esters and analogues of retinoic acid.Type: GrantFiled: July 30, 1999Date of Patent: August 21, 2001Assignee: Georgetown University School of MedicineInventors: Gloria Massaro, Donald Massaro
-
Patent number: 6270806Abstract: Nanoparticulate compositions comprising an insoluble organic drug and at least one polyethylene glycol-derivatized lipid adsorbed on the surface of the drug are described. The polyethylene glycol-derivatized lipid can be a PEG-phospholipid, PEG-cholesterol, PEG-cholesterol derivative, PEG-vitamin A, PEG-vitamin E, or a mixture thereof The compositions have an effective average particle size of less than about 1 micron. The invention also describes methods of making and using such compositions.Type: GrantFiled: March 3, 1999Date of Patent: August 7, 2001Assignee: Elan Pharma International LimitedInventors: Elaine Liversidge, Greta A. Gottardy
-
Patent number: 6270781Abstract: The present invention relates to compositions and methods for treating cell damage caused by reactive oxygen species in relation to a variety of skin disorders. More specifically, the present invention relates to the treatment skin disorders through the topical delivery of reactive oxygen metabolite production or release inhibiting compounds.Type: GrantFiled: January 8, 1999Date of Patent: August 7, 2001Assignee: Maxim Pharmaceuticals, Inc.Inventor: Kurt R. Gehlsen
-
Patent number: 6267948Abstract: A method and dermatological formulation are provided for increasing the pigmentation response of mammalian skin, hair, wool or fur to agents which stimulate melanogenesis. The method comprises administering to mammalian skin, hair, wool or fur a dermatological formulation containing a melanogenesis-stimulating effective amount of an agent which stimulates melanogenesis in melanocytes, and a melanogenesis-enhancing effective amount of an agent, such as an &agr;-hydroxy acid, which enhances the stimulation of melanogenesis by the melanogenesis-stimulation agent.Type: GrantFiled: April 6, 1998Date of Patent: July 31, 2001Assignee: Applied Genetics Incorporated DermaticsInventors: Wu Yun Ren, Michael Seidman, David A. Brown
-
Publication number: 20010009926Abstract: Meso-zeaxanthin compositions for pharmaceutical use and use of meso-zeaxanthin to increase the deposition of macular pigment in the human eye, and for the therapeutic treatment or prophylaxis of diseases and disorders of the macula, in particular age-related macular degeneration (AMD).Type: ApplicationFiled: March 2, 2001Publication date: July 26, 2001Applicant: THE HOWARD FOUNDATIONInventors: Alan Norman Howard, John T. Landrum, Richard A. Bone
-
Patent number: 6264986Abstract: The present invention relates to stable emulsions and dry powders of mixtures of fat-soluble vitamins, and to processes for their preparation and to their use.Type: GrantFiled: October 9, 1997Date of Patent: July 24, 2001Assignee: BASF AktiengesellschaftInventors: Wolfgang Hähnlein, Morten Mohr Hansen, Jes Elenius Olesen, Anne Grethe Tobiasen
-
Patent number: 6265450Abstract: An anti-stress composition having for its active ingredient astaxanthin and/or its ester. This composition can be in the form of a pharmaceutical, functional food, food or beverage and so forth.Type: GrantFiled: October 28, 1996Date of Patent: July 24, 2001Assignees: Suntory Limited, Itano Refrigerated Food Co., Ltd.Inventors: Sumio Asami, Zhi-bo Yang, Eiji Yamashita, Hayao Otoze